ATE207891T1 - Biphenylsulfonamid matrix metalloproteinase inhibitoren - Google Patents
Biphenylsulfonamid matrix metalloproteinase inhibitorenInfo
- Publication number
- ATE207891T1 ATE207891T1 AT97918788T AT97918788T ATE207891T1 AT E207891 T1 ATE207891 T1 AT E207891T1 AT 97918788 T AT97918788 T AT 97918788T AT 97918788 T AT97918788 T AT 97918788T AT E207891 T1 ATE207891 T1 AT E207891T1
- Authority
- AT
- Austria
- Prior art keywords
- matrix metalloproteinase
- metalloproteinase inhibitors
- alkyl
- biphenylsulfonamide
- biphenylsulfonamide matrix
- Prior art date
Links
- SBXDENYROQKXBE-UHFFFAOYSA-N 2-phenylbenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 SBXDENYROQKXBE-UHFFFAOYSA-N 0.000 title 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 title 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 210000002808 connective tissue Anatomy 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- -1 nitro, amino Chemical group 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1746096P | 1996-05-17 | 1996-05-17 | |
| PCT/US1997/006801 WO1997044315A1 (en) | 1996-05-17 | 1997-04-24 | Biphenylsulfonamide matrix metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE207891T1 true ATE207891T1 (de) | 2001-11-15 |
Family
ID=21782716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97918788T ATE207891T1 (de) | 1996-05-17 | 1997-04-24 | Biphenylsulfonamid matrix metalloproteinase inhibitoren |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0901466B1 (enExample) |
| JP (1) | JP2000511175A (enExample) |
| KR (1) | KR20000011095A (enExample) |
| CN (1) | CN1077885C (enExample) |
| AT (1) | ATE207891T1 (enExample) |
| BG (1) | BG63940B1 (enExample) |
| BR (1) | BR9710841A (enExample) |
| CA (1) | CA2253342A1 (enExample) |
| CZ (1) | CZ294063B6 (enExample) |
| DE (1) | DE69707865T2 (enExample) |
| DK (1) | DK0901466T3 (enExample) |
| EA (1) | EA001561B1 (enExample) |
| EE (1) | EE03965B1 (enExample) |
| ES (1) | ES2167733T3 (enExample) |
| IL (1) | IL126832A0 (enExample) |
| NO (1) | NO312510B1 (enExample) |
| NZ (1) | NZ332711A (enExample) |
| PL (1) | PL186416B1 (enExample) |
| PT (1) | PT901466E (enExample) |
| SK (1) | SK282863B6 (enExample) |
| WO (1) | WO1997044315A1 (enExample) |
| ZA (1) | ZA974223B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU690703B2 (en) * | 1994-06-22 | 1998-04-30 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| US6124333A (en) * | 1995-06-22 | 2000-09-26 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
| MXPA99001974A (es) * | 1996-12-09 | 2002-03-27 | Warner Lambert Co | Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular. |
| EP1366765A1 (en) * | 1996-12-17 | 2003-12-03 | Warner-Lambert Company Llc | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing |
| BR9714142A (pt) * | 1996-12-17 | 2000-02-29 | Warner Lambert Co | Uso de inibidores de metaloproteìnases matriciais para tratamento de distúrbios neurológicos e promoção de cicatrização de feridas |
| GB9706255D0 (en) * | 1997-03-26 | 1997-05-14 | Smithkline Beecham Plc | Novel compounds |
| DE19719621A1 (de) * | 1997-05-09 | 1998-11-12 | Hoechst Ag | Sulfonylaminocarbonsäuren |
| ID24105A (id) | 1997-07-22 | 2000-07-06 | Shionogi & Co | Komposisi untuk mengobati atau mencegah glomerulopati |
| BR9814422A (pt) * | 1997-12-23 | 2000-10-10 | Warner Lambert Co | Combinações de inibidor de ace - inibidor de mmp |
| PL342009A1 (en) * | 1998-02-04 | 2001-05-07 | Novartis Ag | Sulphonylamine derivatives capable to inhibit extracellular substance degrading metaloproteinases |
| US6410580B1 (en) | 1998-02-04 | 2002-06-25 | Novartis Ag | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| JP2002506818A (ja) * | 1998-03-17 | 2002-03-05 | ワーナー−ランバート・カンパニー | スタチン−マトリックスメタロプロテイナーゼ阻害剤組み合わせ物 |
| EP0967201A1 (en) * | 1998-05-20 | 1999-12-29 | Roche Diagnostics GmbH | Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors |
| EP1097159B1 (de) | 1998-07-16 | 2002-11-06 | Aventis Pharma Deutschland GmbH | Phosphin- und phosphonsäurederivate als arzneimittel |
| OA11584A (en) * | 1998-07-21 | 2004-07-20 | Warner Lambert Co | Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions. |
| DE19851184A1 (de) | 1998-11-06 | 2000-05-11 | Aventis Pharma Gmbh | N-Arylsulfonyl-aminosäure-omega-amide |
| US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| PL351374A1 (en) * | 1999-04-19 | 2003-04-07 | Shionogi & Co | Sulfonamide derivatives having oxadiazole rings |
| GB9918684D0 (en) | 1999-08-09 | 1999-10-13 | Novartis Ag | Organic compounds |
| WO2001037826A1 (en) | 1999-11-26 | 2001-05-31 | Shionogi & Co., Ltd. | Npyy5 antagonists |
| EP1331224A4 (en) * | 2000-09-29 | 2004-03-17 | Shionogi & Co | THIAZOLE AND OXAZOLE DERIVATIVES |
| GB0103303D0 (en) | 2001-02-09 | 2001-03-28 | Novartis Ag | Organic compounds |
| MXPA01013326A (es) | 2001-02-14 | 2002-08-26 | Warner Lambert Co | Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz. |
| WO2003035610A1 (en) * | 2001-10-26 | 2003-05-01 | Shionogi & Co., Ltd. | Sulfonamide derivative having mmp inhibitory activity |
| GB0314488D0 (en) * | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
| BR0318625A (pt) | 2003-12-04 | 2006-10-31 | Wyeth Corp | biaril sulfonamidas e métodos para usar as mesmas |
| CN101001834B (zh) * | 2004-03-22 | 2011-06-29 | 南方研究院 | 基质金属蛋白酶的非肽抑制剂 |
| CN101279956B (zh) * | 2008-04-25 | 2011-06-15 | 南昌大学 | 一种基质金属蛋白酶抑制剂及合成方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| AU690703B2 (en) * | 1994-06-22 | 1998-04-30 | British Biotech Pharmaceuticals Limited | Metalloproteinase inhibitors |
-
1997
- 1997-04-24 CZ CZ19983668A patent/CZ294063B6/cs not_active IP Right Cessation
- 1997-04-24 ES ES97918788T patent/ES2167733T3/es not_active Expired - Lifetime
- 1997-04-24 KR KR1019980709253A patent/KR20000011095A/ko not_active Ceased
- 1997-04-24 EP EP97918788A patent/EP0901466B1/en not_active Expired - Lifetime
- 1997-04-24 NZ NZ332711A patent/NZ332711A/en unknown
- 1997-04-24 BR BR9710841A patent/BR9710841A/pt not_active IP Right Cessation
- 1997-04-24 CN CN97194719A patent/CN1077885C/zh not_active Expired - Fee Related
- 1997-04-24 WO PCT/US1997/006801 patent/WO1997044315A1/en not_active Ceased
- 1997-04-24 EA EA199800988A patent/EA001561B1/ru not_active IP Right Cessation
- 1997-04-24 DK DK97918788T patent/DK0901466T3/da active
- 1997-04-24 JP JP09542377A patent/JP2000511175A/ja not_active Abandoned
- 1997-04-24 DE DE69707865T patent/DE69707865T2/de not_active Expired - Fee Related
- 1997-04-24 EE EE9800397A patent/EE03965B1/xx not_active IP Right Cessation
- 1997-04-24 IL IL12683297A patent/IL126832A0/xx unknown
- 1997-04-24 CA CA002253342A patent/CA2253342A1/en not_active Abandoned
- 1997-04-24 AT AT97918788T patent/ATE207891T1/de not_active IP Right Cessation
- 1997-04-24 PT PT97918788T patent/PT901466E/pt unknown
- 1997-04-24 SK SK1577-98A patent/SK282863B6/sk unknown
- 1997-04-24 PL PL97329929A patent/PL186416B1/pl not_active IP Right Cessation
- 1997-05-15 ZA ZA9704223A patent/ZA974223B/xx unknown
-
1998
- 1998-11-12 BG BG102918A patent/BG63940B1/bg unknown
- 1998-11-16 NO NO19985326A patent/NO312510B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PL186416B1 (pl) | 2004-01-30 |
| CA2253342A1 (en) | 1997-11-27 |
| PT901466E (pt) | 2002-04-29 |
| EP0901466A1 (en) | 1999-03-17 |
| NO312510B1 (no) | 2002-05-21 |
| ZA974223B (en) | 1997-12-10 |
| KR20000011095A (ko) | 2000-02-25 |
| SK157798A3 (en) | 1999-04-13 |
| AU713286B2 (en) | 1999-11-25 |
| ES2167733T3 (es) | 2002-05-16 |
| JP2000511175A (ja) | 2000-08-29 |
| NZ332711A (en) | 2000-06-23 |
| EP0901466B1 (en) | 2001-10-31 |
| CN1219166A (zh) | 1999-06-09 |
| HK1019585A1 (en) | 2000-02-18 |
| WO1997044315A1 (en) | 1997-11-27 |
| SK282863B6 (sk) | 2002-12-03 |
| PL329929A1 (en) | 1999-04-26 |
| CZ294063B6 (cs) | 2004-09-15 |
| DE69707865D1 (de) | 2001-12-06 |
| CZ366898A3 (cs) | 1999-02-17 |
| EA001561B1 (ru) | 2001-04-23 |
| IL126832A0 (en) | 1999-08-17 |
| AU2680397A (en) | 1997-12-09 |
| BR9710841A (pt) | 1999-08-17 |
| BG63940B1 (bg) | 2003-07-31 |
| EE03965B1 (et) | 2003-02-17 |
| EA199800988A1 (ru) | 1999-04-29 |
| DK0901466T3 (da) | 2002-02-18 |
| NO985326L (no) | 1999-01-14 |
| NO985326D0 (no) | 1998-11-16 |
| EE9800397A (et) | 1999-06-15 |
| BG102918A (en) | 1999-09-30 |
| DE69707865T2 (de) | 2002-05-02 |
| CN1077885C (zh) | 2002-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69707865D1 (de) | Biphenylsulfonamid matrix metalloproteinase inhibitoren | |
| RU2221781C2 (ru) | Тиолсульфоновые соединения в качестве ингибитора матриксной металлопротеазы и способы лечения | |
| AU6894800A (en) | Caspase inhibitors and uses thereof | |
| GB9801690D0 (en) | Therapeutic agents | |
| UY25322A1 (es) | Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis | |
| WO2003024448A3 (en) | Inhibitors of histone deacetylase | |
| ATE289590T1 (de) | Beta-sulfonyl-hydroxamsäuren als matrix- metalloproteinaseinhibitoren | |
| DE69612003D1 (de) | Substituierte benzolaktamverbindungen als substanz-p-antagonisten | |
| DK0705254T3 (da) | Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer | |
| BG105369A (en) | Arylpiperazines and their use as metalloproteinase inhibiting agent (mmp | |
| EA200101085A1 (ru) | Гидроксамовые кислоты, производные ароматических сульфонов, - ингибиторы металлопротеаз | |
| EA200100804A1 (ru) | Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз | |
| DK0946166T3 (da) | Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling | |
| TR199902923T2 (xx) | Yumu�ak kas h�cresi �o�almas� inhibit�rleri olarak (imidazol-5-il)metil-2-kuinolinon t�revleri. | |
| PT1250340E (pt) | Metodos e compostos para inibicao de mrp1 | |
| AU2001255646A1 (en) | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives | |
| DE69736945D1 (de) | Biphenylverbindungen sowie ihre anwendung als östrogene mittel | |
| GR3032698T3 (en) | Organic compounds | |
| ATE282602T1 (de) | Buttersäure matrix-metalloproteinase-inhibitoren | |
| NZ516620A (en) | 1,4-substituted 4,4-diaryl cyclohexanes | |
| BR0214886A (pt) | Fenilalquinos | |
| ES2173634T3 (es) | Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf. | |
| PT971714E (pt) | Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |